Scynexis Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 29

Employees

  • Stock Symbol
  • SCYX

Stock Symbol

  • Share Price
  • $1.29
  • (As of Wednesday Closing)

Scynexis General Information

Description

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1 Evertrust Plaza
  • 13th Floor
  • Jersey City, NJ 07302
  • United States
+1 (201)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 1 Evertrust Plaza
  • 13th Floor
  • Jersey City, NJ 07302
  • United States
+1 (201)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Scynexis Stock Performance

As of 13-Nov-2024, Scynexis’s stock price is $1.29. Its current market cap is $48.9M with 37.9M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.29 $1.34 $1.25 - $3.07 $48.9M 37.9M 148K -$0.76

Scynexis Financials Summary

As of 30-Sep-2024, Scynexis has a trailing 12-month revenue of $8.57M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV (1,088) 9,707 3,316 88,703
Revenue 8,566 140,141 5,091 13,163
EBITDA (39,993) 66,935 (63,120) (33,118)
Net Income (36,441) 67,041 (62,809) (32,866)
Total Assets 99,038 128,412 87,810 119,837
Total Debt 15,898 15,080 48,597 43,626
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Scynexis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Scynexis‘s full profile, request access.

Request a free trial

Scynexis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Scynexis‘s full profile, request access.

Request a free trial

Scynexis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infective
Drug Discovery
Jersey City, NJ
29 As of 2023

Waltham, MA
 

King of Prussia, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Scynexis Competitors (39)

One of Scynexis’s 39 competitors is Entasis Therapeutics, a Corporate Backed or Acquired company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Entasis Therapeutics Corporate Backed or Acquired Waltham, MA
Paratek Pharmaceuticals Private Equity-Backed King of Prussia, PA
Spero Therapeutics Formerly VC-backed Cambridge, MA
Peloton Therapeutics Formerly VC-backed Dallas, TX
Lixte Biotechnology Holdings Corporation Pasadena, CA
You’re viewing 5 of 39 competitors. Get the full list »

Scynexis Patents

Scynexis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020276595-A1 Antifungal agents for candida auris decolonization Pending 16-May-2019
EP-3968986-A1 Antifungal agents, like ibrexafungerp for candida auris decolonization Pending 16-May-2019
US-20220211684-A1 Antifungal agents for candida auris decolonization Pending 16-May-2019
CA-3140637-A1 Antifungal agents, like ibrexafungerp for candida auris decolonization Pending 16-May-2019
AU-2020228036-A1 Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia Pending 27-Feb-2019 A61K31/4439
To view Scynexis’s complete patent history, request access »

Scynexis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Scynexis Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Scynexis‘s full profile, request access.

Request a free trial

Scynexis ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Scynexis’s complete esg history, request access »

Scynexis FAQs

  • When was Scynexis founded?

    Scynexis was founded in 1999.

  • Where is Scynexis headquartered?

    Scynexis is headquartered in Jersey City, NJ.

  • What is the size of Scynexis?

    Scynexis has 29 total employees.

  • What industry is Scynexis in?

    Scynexis’s primary industry is Drug Discovery.

  • Is Scynexis a private or public company?

    Scynexis is a Public company.

  • What is Scynexis’s stock symbol?

    The ticker symbol for Scynexis is SCYX.

  • What is the current stock price of Scynexis?

    As of 13-Nov-2024 the stock price of Scynexis is $1.29.

  • What is the current market cap of Scynexis?

    The current market capitalization of Scynexis is $48.9M.

  • What is Scynexis’s current revenue?

    The trailing twelve month revenue for Scynexis is $8.57M.

  • Who are Scynexis’s competitors?

    Entasis Therapeutics, Paratek Pharmaceuticals, Spero Therapeutics, Peloton Therapeutics, and Lixte Biotechnology Holdings are some of the 39 competitors of Scynexis.

  • What is Scynexis’s annual earnings per share (EPS)?

    Scynexis’s EPS for 12 months was -$0.76.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »